---
title: "Biogen Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296954963.md"
description: "Biogen Inc. (BIIB) shares rose 1.21% to $220.77, outperforming peers like Johnson & Johnson and Pfizer on a strong trading day. This marks the third consecutive gain, with the stock closing just short of its 52-week high of $222.15. Despite the rise, Biogen's trading volume remained significantly below its 50-day average."
datetime: "2026-08-25T20:59:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296954963.md)
  - [en](https://longbridge.com/en/news/296954963.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296954963.md)
generator: "portal-rs"
---

# Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Biogen Inc. (BIIB) advanced 1.21% to $220.77 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.32% to 7,677.28 and the Dow Jones Industrial Average rising 0.30% to 53,577.40.

This was the stock's third consecutive day of gains.

Biogen Inc. closed 0.62% short of its 52-week high of $222.15, which the company reached on August 19th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.53% to $273.14, Pfizer Inc. (PFE) rose 2.15% to $28.57, and AbbVie Inc. (ABBV) rose 0.48% to $265.79.

Trading volume (495,313) remained 712,698 below its 50-day average volume of 1.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 25, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

08-25-26 1659ET

### Related Stocks

- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Amundi Purchases 726,004 Shares of Biogen Inc. $BIIB](https://longbridge.com/en/news/298275504.md)
- [Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology](https://longbridge.com/en/news/298815400.md)
- [Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing](https://longbridge.com/en/news/298400767.md)
- [Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience](https://longbridge.com/en/news/298993068.md)
- [Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI(R) (lecanemab) for Early Alzheimer's Disease](https://longbridge.com/en/news/298340520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**